Drug Type Enzyme |
Synonyms Herceptin Hylecta, Herceptin SC, Hyaluronidase-trastuzumab + [6] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Hyaluronic acid modulators, ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (28 Feb 2019), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Breast Cancer | US | 28 Feb 2019 | |
HER2 Positive Breast Cancer | US | 28 Feb 2019 |
Not Applicable | 70 | ljlnqcfhgk(wgywmwatdw) = njefzjdkta cfkzunyrbv (hynexxldyi ) View more | Positive | 05 Dec 2023 | |||
Phase 3 | 500 | Post-operative Radiotherapy+Trastuzumab SC+Trastuzumab IV+CYCLOPHOSPHAMIDE+Doxorubicin+Paclitaxel+Pertuzumab IV+Docetaxel | ulbzpuejug(cmgxuuyfgc) = cfhoqamwgv qtcxguwqil (juplnjhenw, oppmimzutt - ldsmudywsn) View more | - | 25 Jun 2020 | ||
Not Applicable | 70 | nxgticdpvg(akrlnziozm) = mrpyhfpoan whpulshgpa (sskdisqguz ) View more | Positive | 01 Oct 2019 |